Business
4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 2023 NACFC
4D-710 interim data to be presented in plenary and symposium sessions at the North American Cystic Fibrosis Conference in Phoenix, Arizona held on November
About this update from 4d Molecular Therapeutics, Inc.
[{"type":"text","content":"4D-710 interim data to be presented in plenary and symposium sessions at the North American Cystic Fibrosis Conference in Phoenix, Arizona held on November 2-4, 2023Company to host webcast on Wednesday, November 1, 2023 at 4:30 p.m. ET EMERYVILLE, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a clinical-stage genetic medicines company with three novel, highly targeted next generation AAV vectors currently in the clinic, today announced that interim data from the Phase 1/2 AEROW clinical trial of aerosolized 4D-710 for treatment of cystic fibrosis lung disease will be presented at the 2023 North American Cystic Fibrosis Conference (NACFC) and that it will host a live webcast to discuss the data in detail and provide a program update on Wednesday, November 1, 2023 at 4:30 p.m. ET. The interim data will include additional safety and clinical activity follow-up on Cohort 1 (n=3) at the 1E15 vg dose level and initial safety and biomarker data from Cohort 2 (n=3-6) at the 2E15 vg dose level. The Company previously announced positive interim data from Cohort 1 at the European Cystic Fibrosis Society 46th Annual Meeting. 2023 NACFC Presentation Details: Plenary Session:Genetic Therapies for All: Harnessing Cross-Disease Knowledge for Breakthroughs in Cystic FibrosisDate/Time:Thursday, November 2, 2023 at 4:30 p.m. MSTPresenter:Paul McCray, Jr., MD, University of Iowa Symposium Session:Building the Path to the Cure: the role of AAV therapyDate/Time:Friday, November 3, 2023 at 3:30 p.m. MSTPresenter:Jennifer L. Taylor-Cousar, MD, National Jewish Health Webcast Details: Title:4D-710 Phase 1/2 AEROW Interim Clinical Data and Program Update Webcast and Q&ADate/Time:Wednesday, November 1, 2023 at 4:30 p.m. ETRegistration:Link An archived copy of the webcast will be available for up to one year by visiting the “Investors & Media” section of the 4DMT website at the following link: https://ir.4dmoleculartherapeutics.com/events. About 4D-710 and Cystic Fibrosis Lung Disease 4D-710 is comprised of our targeted and evolved next generation vector, A101, and a codon-optimized CFTR∆R transgene. 4D-710 has the potential to treat a broad range of people with cystic fibrosis, independent of the specific CFTR mutation, and is designed for aerosol delivery to achieve CFTR expression within lung air...